PIC Therapeutics is a biotechnology company focused on fundamentally changing how cancer is treated by developing a new generation of therapeutics based on the modulation of RNA translation
PIC Therapeutics’ precision-based therapeutics target the “master switch” of cancer signalling pathways, selectively blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation.
PIC Therapeutics’ selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.
CEO Katherine Bowdish
Advent Contact Alan Walts
PIC Therapeutics Completes $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer
Press Release. Financing Round Led by OrbiMed with participation from Lumira Ventures, Harrington Discovery Institute and existing investors Advent Life Sciences and Belinda Termeer Therapy development focused on addressing…Read More
PIC Therapeutics Appoints Dr. Katherine Bowdish as Chief Executive Officer
Press Release. NATICK, MA – August 12, 2020 – PIC Therapeutics (“PIC”), a biotechnology company focused on transforming the treatment of cancer through the selective modulation of oncogene translation,…Read More
PIC Therapeutics Raises $5 Million to Advance Development of Small Molecules That Selectively Modulate eIF4E
Press Release. Series Seed Equity Round led by Advent Life Sciences BOSTON--(BUSINESS WIRE)--PIC Therapeutics (“PIC”), a biotechnology company focused on transforming the treatment of cancer though the selective modulation…Read More